Clinical trial NCT04730193: Caffeine and Cerebrovascular Reactivity
Official title: The Effect of Caffeine on Cerebrovascular and Retinal Microvessel Reactivity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Caffeine
Keywords: caffeine
Cerebrovascular reactivity
Retinal reactivity
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2021-01-29
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: subject will take drug A on first session and measurements will be performed at baseline and 1 hour after treatment; subject will come for second visit in 5-7 days and take drug B, measurements will be performed at baseline and 1 hour after treatment
Primary purpose: OTHER

Brief summary: Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

Detailed description: Normal brain function is critically dependent on moment-to-moment adjustment of cerebral blood flow to match demands of activated neurons. This process is known as neurovascular coupling (NVC) and recent in vivo studies demonstrate that impairment of NVC responses is associated with worse cognitive performance. Several methods are available to measure NVC responses in human subjects, including transcranial Doppler (TCD), functional near infrared spectroscopy (fNIRS), and dynamic retinal vessel analysis (DVA). Although all these methodologies aim to measure hemodynamic changes in the brain vasculature in response to cognitive, motor, or visual stimulation, the responses are evaluated on the different levels of cerebral vasculature including microvasculature (fNIRS), large cerebral vessels such as middle cerebral artery (TCD), or in the arterioles and venules of the retina (DVA). Currently, there are limited data available on the simultaneous assessment of NVC responses using these methodologies.

Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vasculature. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

This study is designed to establish the direct link between reactivity in the cerebral and retinal micro- and macrovasculature. To achieve this goal, a prospective, single-blinded, placebo controlled, cross-over study will be employed to evaluate changes in the NVC responses measured simultaneously with DVA and TCD, or DVA and fNIRS before and after administration of 100mg of incapsulated caffeine or placebo pill.

Eligibility criteria: Inclusion Criteria:

* English speaking
* Ability to read and write in English
* Competence to provide informed consent
* Non-occludable angle and with no optic neuropathy
* Subjects will be asked to refrain from caffeine consumption for at least 8 hours before participating in the study

Exclusion Criteria:

* The history of photosensitive epilepsy
* Intraocular pressure 21 Hgmm or higher
* Eyes with a visual acuity 20/30 or lower or the inability to fixate on fixation markers
* Previous symptoms of glaucoma attack (severe ocular pain and redness, decreased vision, colored halos in combination with headache, nausea and vomiting).
* Known allergies to study drugs
* Pregnancy and breast feeding
* Significant cardiac disease (e.g. heart failure), chest pain in the last 6 months
* Stage-2 high blood pressure not controlled by medication (\>160/100 mm Hg)
* Uncontrolled diabetes mellitus; History of stroke; Multiple sclerosis; Chronic obstructive pulmonary disease; Active cancer; Abnormal liver function
* Diagnosis of dementia; Anxiety Disorder
* Absent temporal acoustic windows, intracranial stenosis (for TCD-related studies)
* History of arrhythmias
* Prisoners

Primary outcomes:
measure: Modified Caffeine Research Visual Analogue Scales
timeFrame: Change from baseline measurements 1 hour after treatment
measure: Static retinal vessel assessment
timeFrame: Change from baseline measurements 1 hour after treatment
measure: Dynamic retinal vessel assessment
timeFrame: Change from baseline measurements 1 hour after treatment
measure: Cerebrovascular reactivity using transcranial Doppler
timeFrame: Change from baseline measurements 1 hour after treatment
measure: Cerebrovascular reactivity using functional near infrared spectroscopy (fNIRS)
timeFrame: Change from baseline measurements 1 hour after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Translational GeroScience Laboratory
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Andriy Yabluchanskiy, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: